# Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

> **NCT04976283** · PHASE4 · UNKNOWN · sponsor: **Getz Pharma** · enrollment: 123 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2
- NASH - Nonalcoholic Steatohepatitis
- NAFLD

## Interventions

- **DRUG:** Pioglitazone
- **DRUG:** Empagliflozin
- **DRUG:** Pioglitazone + Empagliflozin

## Key facts

- **NCT ID:** NCT04976283
- **Lead sponsor:** Getz Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-15
- **Primary completion:** 2023-05-15
- **Final completion:** 2023-11-15
- **Target enrollment:** 123 (ESTIMATED)
- **Last updated:** 2022-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04976283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04976283, "Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver". Retrieved via AI Analytics 2026-09-14 from https://api.ai-analytics.org/clinical/NCT04976283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*